Gene therapy. RAC's advice: proceed with caution.
Kaiser
Jocelyn
J
D048868:Adaptor Proteins, Signal Transducing; D026683:Advisory Committees; D002648:Child; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000592:standards; D004274:DNA, Recombinant; D004268:DNA-Binding Proteins / Q000235:genetics; D020022:Genetic Predisposition to Disease; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors; D006801:Humans; D007258:Informed Consent; D060588:LIM Domain Proteins; D015458:Leukemia, T-Cell / Q000209:etiology* / Q000235:genetics; D008667:Metalloproteins / Q000235:genetics; D009316:National Institutes of Health (U.S.); D011518:Proto-Oncogene Proteins; D012190:Retroviridae / Q000235:genetics; D016511:Severe Combined Immunodeficiency / Q000628:therapy*; D014178:Translocation, Genetic; D014481:United States; D014486:United States Food and Drug Administration
D048868:Adaptor Proteins, Signal Transducing; D004274:DNA, Recombinant; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D011518:Proto-Oncogene Proteins